YM BIOSCIENCES Selects Chair for Pivotal Cancer Trial

Share Name	Share Symbol	Market	Type	Share ISIN	Share Description
YM Bio. Com Shs	LSE:YMBA	London	Ordinary Share	CA9842381050	COM SHS NPV

Industry Sector	Turnover	Profit	EPS - Basic	PE Ratio	Market Cap
	0	0		N/A	0

YM Bio. Com Shs (LSE:YMBA)
Historical Stock Chart

From May 2019 to May 2024

Click Here for more YM Bio. Com Shs Charts.

YM BIOSCIENCES Selects Chair for Pivotal Cancer Trial MISSISSAUGA, ON, March 30 /PRNewswire-FirstCall/ -- YM BioSciences Inc. (TSX:YM, AIM:YMBA), the cancer drug development company, today announced that Dr. Kathleen Pritchard, M.D., F.R.C.P.C., hasagreed to act as the North American Chair for the Company's upcoming international pivotal DEC study in patients with metastatic breast cancer. The DEC study is a multinational randomized Phase III clinical trial for YM's lead drug, tesmilifene, whichwill be combined with epirubicin/cyclophosphamide. The trial is designed to confirm the survival advantage demonstrated in a previous Phase III study ("MA19") where tesmilifene was used in combination with the anthracycline doxorubicin to treat patients with metastatic breast cancer. In the first Phase III trial, the combination resulted in an overall survival advantage of greater than 50% over the standard of care alone. "Dr. Pritchard, of Sunnybrook and Women's College Health Sciences Centre in Toronto, is an internationally regarded oncologist who will ensure this important trial is performed under the highest standards," said Mr. David Allan, Chairman and CEO of YM BioSciences. "With this key step completed, we look forward to commencing this trial in the coming weeks." Dr. Pritchard has held leadership roles in a number of national and international multi-centre clinical trials, is a member of scientific advisory boards for clinical trials world-wide and is widely published in the major cancer and general medical journals. Dr. Pritchard holds the following positions: - Professor, Departments of Medicine and Public Health Sciences, University of Toronto - Chair, Breast Cancer Site Group, Toronto Sunnybrook Regional Cancer Centre, Sunnybrook & Women's College Health Sciences Centre - Head, Division of Clinical Trials & Epidemiology, Toronto Sunnybrook Regional Cancer Centre About Tesmilifene Tesmilifene, a small molecule chemopotentiator (for taxanes and anthracyclines), was originally developed by Dr. L.J. Brandes of the University of Manitoba and CancerCare Manitoba and licensed by them to YM in 2000. It has previously completed an international 305-patient Phase III trial in which significant survival results were demonstrated in women with metastatic breast cancer. The current Phase III trial is designed to gain approval for the drug. The drug has been clinically demonstrated to increase the effectiveness of the current principal chemotherapeutic drugs, anthracyclines and taxanes, which are used in the majority of cancers. About YM BioSciences YM BioSciences Inc. is a cancer drug development company. In addition to tesmilifene, the Company is developing an EGFr humanized monoclonal antibody that has completed Phase II trials and a GnRH anti-cancer vaccine also in clinical trials. YM is also supporting the preclinical development of two additional cancer products. Except for historical information, this press release may contain forward-looking statements, which reflect the Company's current expectation regarding future events. These forward-looking statements involve risk and uncertainties, which may cause but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process and other risks detailed from time to time inthe Company's ongoing quarterly and annual reporting. DATASOURCE: YM BioSciences Inc. CONTACT: James Smith, The Equicom Group Inc., Tel. +1 (416) 815-0700 x229, Email: ; YM BioSciences Inc., Tel. +1 (905) 629-9761, Fax +1 (905) 629-4959, Email:

Market Data

News

Trading Tools

Markets

Discover

Hot Features

Follow Feed

Options Flow

Monitor

YMBA YM Bio. Com Shs